1. Rigel Pharmaceuticals will present at the Jefferies Global Healthcare Conference. 2. CEO Raul Rodriguez will discuss company overview on June 4, 2025. 3. The event emphasizes Rigel's focus on hematologic disorders and cancer. 4. Investors can access the presentation via Rigel's website. 5. Rigel's portfolio includes novel therapies aimed at patient improvement.
Company presentations at healthcare conferences often bolster investor confidence and visibility. Historical examples show positive stock reactions to successful conference presentations.
The announcement indicates active corporate engagement and potential revenue generation efforts, which typically correlate with stock performance.
The presentation offers immediate engagement with investors, potentially affecting stock prices shortly after the event. However, long-term effects depend on the outcomes discussed.
SOUTH SAN FRANCISCO, Calif., May 28, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 12:50 p.m. ET in New York, NY.
To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.
Investors: Rigel Pharmaceuticals, Inc. 650.624.1232 [email protected]
Media: David Rosen Argot Partners 646.461.6387 [email protected]
SOURCE Rigel Pharmaceuticals, Inc.